Susquehanna International Group, LLP Uni Qure N.V. Put Options Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 15, 2024	SELL	$4.39 - $5.43 $1.24 Million - $1.53 Million	-281,700 Reduced 54.46%	235,600 $1.06 Million
Q1 2024 May 07, 2024	BUY	$4.82 - $6.93 $2.15 Million - $3.1 Million	446,800 Added 633.76%	517,300 $2.69 Million
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $263,484 - $387,036	-46,800 Reduced 39.9%	70,500 $477,000
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $2.32 Million - $4.09 Million	-345,900 Reduced 74.68%	117,300 $787,000
Q2 2023 Aug 11, 2023	BUY	$11.12 - $22.2 $4.76 Million - $9.5 Million	427,900 Added 1212.18%	463,200 $5.31 Million
Q1 2023 May 16, 2023	SELL	$18.7 - $23.07 $460,020 - $567,522	-24,600 Reduced 41.07%	35,300 $710,000
Q4 2022 Feb 14, 2023	SELL	$18.12 - $27.32 $918,684 - $1.39 Million	-50,700 Reduced 45.84%	59,900 $1.36 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $439,782 - $661,486	-25,900 Reduced 18.97%	110,600 $2.08 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.